Form 4: Neurogene Inc. Executive Julie Jordan Reports Acquisition of Stock and Options

Chief Medical Officer Julie Jordan reports acquiring 8,400 shares of common stock and options to purchase 50,300 shares of Neurogene Inc. stock.

Summary

• Julie Jordan, Chief Medical Officer of Neurogene Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of 8,400 shares of common stock and options to purchase 50,300 shares of Neurogene Inc. stock on March 26, 2025.
• The 8,400 shares are restricted stock units that vest in three equal annual installments starting on the first anniversary of the grant date.
• Options for 50,300 shares vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal monthly installments over the following three years.
• The exercise price for the options is $16.14.
• The options expire on March 26, 2035.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard regulatory filing. The acquisition of shares and options by an executive could be interpreted as slightly positive, but it's not a strong indicator.

Positives

• The acquisition of shares and options by a key executive could be seen as a positive sign of confidence in the company's future.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The acquisition of shares and options by a key executive could increase shareholder confidence.

Key Dates

Keywords

Form 4, Neurogene Inc., Julie Jordan, Stock Options, Restricted Stock Units, Beneficial Ownership, Chief Medical Officer, NGNE